ArticlePhysics and imaging in radiation oncology2025
Demonstration of motion-compensated volumetric modulated arc radiotherapy on an MR-linac.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Magnetic Resonance Guided Radical Radiation Therapy for Prostate Cancer in the Presence of Bilateral Hip Prostheses: First Experience With a 1.5 T Magnetic Resonance Linear Accelerator.Advances in radiation oncology · 2026Article
- TrackRAD2025 challenge dataset: real-time tumor tracking for MRI-guided radiotherapy.Medical physics · 2025Article
- Recent technical advancements and clinical applications of MR-guided radiotherapy in lung cancer treatment.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intensity-modulated radiotherapy (IMRT) in combination with magnetic resonance imaging (MRI)-guided gated delivery represents the latest development in the treatment of abdominothoracic tumours on MR-linac. In contrast, volumetric-modulated arc therapy (VMAT) is typically used on conventional linacs due to its superior delivery efficiency and speed. Non-inferior VMAT plans were created in a research treatment planning system for eight lung cancer patients previously treated on an MR-linac. VMAT plans were delivered on a moving dosimeter using respiratory multi-leaf collimator (MLC) tracking. VMAT with MLC tracking achieved an average 2%/2 mm local gamma pass rate of 93% relative to planned dose with a delivery efficiency of 83%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.